CL2014002576A1 - Un metodo para tratar a un sujeto que tenga cancer que comprende administrar 1-(1(4-metil-5-(2-(2,2,2-trifluoro-1,1-dimetil-etil)-piridin-4-il)-tiazol-2-il)-amida) de 2-amida del acido (s)-pirrolidin-1,2-dicarboxilico en un sujeto que tenga una glutamina en la posicion 859 de la subunidad catalitica p110alfa de pi3k. - Google Patents

Un metodo para tratar a un sujeto que tenga cancer que comprende administrar 1-(1(4-metil-5-(2-(2,2,2-trifluoro-1,1-dimetil-etil)-piridin-4-il)-tiazol-2-il)-amida) de 2-amida del acido (s)-pirrolidin-1,2-dicarboxilico en un sujeto que tenga una glutamina en la posicion 859 de la subunidad catalitica p110alfa de pi3k.

Info

Publication number: CL2014002576A1
Authority: CL; Chile
Prior art keywords: amide; subject; acid; p110alpha; pi3k
Prior art date: 2012-03-29

Application number

CL2014002576A

Other languages

English (en)

Inventor

Pascal Furet

Christine Fritsch

Sauveur Michel Maria

Original Assignee

Novartis Ag

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2012-03-29

Filing date

2014-09-26

Publication date

2015-01-23

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=48083130&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CL2014002576(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2014-09-26 Application filed by Novartis Ag filed Critical Novartis Ag

2015-01-23 Publication of CL2014002576A1 publication Critical patent/CL2014002576A1/es

Links

OAWXZFGKDDFTGS-BYPYZUCNSA-N (2s)-pyrrolidine-1,2-dicarboxylic acid Chemical compound OC(=O)[C@@H]1CCCN1C(O)=O OAWXZFGKDDFTGS-BYPYZUCNSA-N 0.000 title 1
IHGVAVLSTPCCJP-UHFFFAOYSA-N 4-methyl-5-[2-(1,1,1-trifluoro-2-methylpropan-2-yl)pyridin-4-yl]-1,3-thiazol-2-amine Chemical compound N1=C(N)SC(C=2C=C(N=CC=2)C(C)(C)C(F)(F)F)=C1C IHGVAVLSTPCCJP-UHFFFAOYSA-N 0.000 title 1
206010028980 Neoplasm Diseases 0.000 title 1
102100038332 Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform Human genes 0.000 title 1
101710093328 Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform Proteins 0.000 title 1
239000002253 acid Substances 0.000 title 1
201000011510 cancer Diseases 0.000 title 1
230000003197 catalytic effect Effects 0.000 title 1
ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 title 1
125000000404 glutamine group Chemical group N[C@@H](CCC(N)=O)C(=O)* 0.000 title 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/156—Polymorphic or mutational markers

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Organic Chemistry (AREA)
Proteomics, Peptides & Aminoacids (AREA)
General Health & Medical Sciences (AREA)
Engineering & Computer Science (AREA)
Wood Science & Technology (AREA)
Genetics & Genomics (AREA)
Zoology (AREA)
Immunology (AREA)
Analytical Chemistry (AREA)
Pathology (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Bioinformatics & Cheminformatics (AREA)
Physics & Mathematics (AREA)
Biochemistry (AREA)
Epidemiology (AREA)
Hospice & Palliative Care (AREA)
Biophysics (AREA)
Biotechnology (AREA)
Microbiology (AREA)
Molecular Biology (AREA)
General Engineering & Computer Science (AREA)
Oncology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Investigating Or Analysing Biological Materials (AREA)

CL2014002576A 2012-03-29 2014-09-26 Un metodo para tratar a un sujeto que tenga cancer que comprende administrar 1-(1(4-metil-5-(2-(2,2,2-trifluoro-1,1-dimetil-etil)-piridin-4-il)-tiazol-2-il)-amida) de 2-amida del acido (s)-pirrolidin-1,2-dicarboxilico en un sujeto que tenga una glutamina en la posicion 859 de la subunidad catalitica p110alfa de pi3k. CL2014002576A1 (es)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US201261617284P	2012-03-29	2012-03-29
US201361767848P	2013-02-22	2013-02-22

Publications (1)

Publication Number	Publication Date
CL2014002576A1 true CL2014002576A1 (es)	2015-01-23

Family

ID=48083130

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
CL2014002576A CL2014002576A1 (es)	2012-03-29	2014-09-26	Un metodo para tratar a un sujeto que tenga cancer que comprende administrar 1-(1(4-metil-5-(2-(2,2,2-trifluoro-1,1-dimetil-etil)-piridin-4-il)-tiazol-2-il)-amida) de 2-amida del acido (s)-pirrolidin-1,2-dicarboxilico en un sujeto que tenga una glutamina en la posicion 859 de la subunidad catalitica p110alfa de pi3k.

Country Status (25)

Country	Link
US (1)	US9795596B2 (es)
EP (1)	EP2830621B1 (es)
JP (1)	JP6224067B2 (es)
KR (1)	KR20140138771A (es)
CN (1)	CN104271136A (es)
AR (1)	AR090544A1 (es)
AU (1)	AU2013241752B2 (es)
BR (1)	BR112014023530A2 (es)
CA (1)	CA2866127A1 (es)
CL (1)	CL2014002576A1 (es)
CO (1)	CO7091176A2 (es)
EA (1)	EA028984B1 (es)
EC (1)	ECSP14025016A (es)
ES (1)	ES2845560T3 (es)
GT (1)	GT201400206A (es)
HK (1)	HK1200723A1 (es)
IL (1)	IL234658B (es)
IN (1)	IN2014DN08970A (es)
MX (1)	MX2014011682A (es)
NZ (1)	NZ628596A (es)
PH (1)	PH12014502168A1 (es)
SG (2)	SG10201608001RA (es)
TW (1)	TW201345525A (es)
WO (1)	WO2013144249A1 (es)
ZA (1)	ZA201405938B (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
BR112015021846A2 (pt) *	2013-03-15	2017-07-18	Novartis Ag	biomarcador
EP3140427B1 (en)	2014-05-09	2020-10-14	Memorial Sloan Kettering Cancer Center	Biomarkers for response to pi3k inhibitors
EP3200772B1 (en) *	2014-10-03	2022-08-03	Novartis AG	Pharmaceutical compositions comprising alpelisib
RU2018123524A (ru) *	2015-12-03	2020-01-09	Новартис Аг	Фармацевтическая диагностика
WO2019199860A1 (en) *	2018-04-09	2019-10-17	The Research Foundation For The State University Of New York	Genetically modified t-cells and pi3k/akt inhibitors for cancer treatment

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4965188A (en)	1986-08-22	1990-10-23	Cetus Corporation	Process for amplifying, detecting, and/or cloning nucleic acid sequences using a thermostable enzyme
EP0359789B1 (en)	1988-01-21	1993-08-04	Genentech, Inc.	Amplification and detection of nucleic acid sequences
CA1340807C (en)	1988-02-24	1999-11-02	Lawrence T. Malek	Nucleic acid amplification process
US5130238A (en)	1988-06-24	1992-07-14	Cangene Corporation	Enhanced nucleic acid amplification process
ATE138106T1 (de)	1988-07-20	1996-06-15	David Segev	Verfahren zur amplifizierung und zum nachweis von nukleinsäuresequenzen
US5169766A (en)	1991-06-14	1992-12-08	Life Technologies, Inc.	Amplification of nucleic acid molecules
US5846717A (en)	1996-01-24	1998-12-08	Third Wave Technologies, Inc.	Detection of nucleic acid sequences by invader-directed cleavage
US5605798A (en)	1993-01-07	1997-02-25	Sequenom, Inc.	DNA diagnostic based on mass spectrometry
GB2453173A (en)	2007-09-28	2009-04-01	Dxs Ltd	Polynucleotide primers
AU2009269087A1 (en) *	2008-07-07	2010-01-14	Xcovery Holding Company Llc	PI3K isoform selective inhibitors
UA104147C2 (uk) *	2008-09-10	2014-01-10	Новартис Аг	Похідна піролідиндикарбонової кислоти та її застосування у лікуванні проліферативних захворювань
CN101445832B (zh) *	2008-12-23	2011-09-14	广州益善生物技术有限公司	Pik3ca基因突变的检测探针、液相芯片及其检测方法
AR082418A1 (es) *	2010-08-02	2012-12-05	Novartis Ag	Formas cristalinas de 1-(4-metil-5-[2-(2,2,2-trifluoro-1,1-dimetil-etil)-piridin-4-il]-tiazol-2-il)-amida de 2-amida del acido (s)-pirrolidin-1,2-dicarboxilico

2013
- 2013-03-27 EP EP13715169.2A patent/EP2830621B1/en active Active
- 2013-03-27 US US14/387,653 patent/US9795596B2/en not_active Expired - Fee Related
- 2013-03-27 NZ NZ628596A patent/NZ628596A/en not_active IP Right Cessation
- 2013-03-27 HK HK15101259.7A patent/HK1200723A1/xx unknown
- 2013-03-27 BR BR112014023530A patent/BR112014023530A2/pt not_active IP Right Cessation
- 2013-03-27 KR KR1020147026735A patent/KR20140138771A/ko not_active Ceased
- 2013-03-27 ES ES13715169T patent/ES2845560T3/es active Active
- 2013-03-27 CN CN201380017393.0A patent/CN104271136A/zh active Pending
- 2013-03-27 CA CA 2866127 patent/CA2866127A1/en not_active Abandoned
- 2013-03-27 AU AU2013241752A patent/AU2013241752B2/en not_active Ceased
- 2013-03-27 AR ARP130101029 patent/AR090544A1/es unknown
- 2013-03-27 MX MX2014011682A patent/MX2014011682A/es unknown
- 2013-03-27 IN IN8970DEN2014 patent/IN2014DN08970A/en unknown
- 2013-03-27 SG SG10201608001RA patent/SG10201608001RA/en unknown
- 2013-03-27 WO PCT/EP2013/056600 patent/WO2013144249A1/en not_active Ceased
- 2013-03-27 JP JP2015502341A patent/JP6224067B2/ja not_active Expired - Fee Related
- 2013-03-27 EA EA201491787A patent/EA028984B1/ru not_active IP Right Cessation
- 2013-03-27 SG SG11201405169SA patent/SG11201405169SA/en unknown
- 2013-03-28 TW TW102111262A patent/TW201345525A/zh unknown
2014
- 2014-08-13 ZA ZA2014/05938A patent/ZA201405938B/en unknown
- 2014-09-15 IL IL234658A patent/IL234658B/en not_active IP Right Cessation
- 2014-09-26 PH PH12014502168A patent/PH12014502168A1/en unknown
- 2014-09-26 CL CL2014002576A patent/CL2014002576A1/es unknown
- 2014-09-29 CO CO14215143A patent/CO7091176A2/es unknown
- 2014-09-29 GT GT201400206A patent/GT201400206A/es unknown
- 2014-10-29 EC ECIEPI201425016A patent/ECSP14025016A/es unknown

Also Published As

Publication number	Publication date
JP6224067B2 (ja)	2017-11-01
MX2014011682A (es)	2015-01-22
IL234658B (en)	2018-02-28
CN104271136A (zh)	2015-01-07
EP2830621B1 (en)	2020-10-21
KR20140138771A (ko)	2014-12-04
SG11201405169SA (en)	2014-10-30
EA201491787A1 (ru)	2015-01-30
JP2015514080A (ja)	2015-05-18
GT201400206A (es)	2017-09-28
WO2013144249A1 (en)	2013-10-03
CO7091176A2 (es)	2014-10-21
AU2013241752B2 (en)	2016-07-07
AU2013241752A1 (en)	2014-09-25
EP2830621A1 (en)	2015-02-04
AR090544A1 (es)	2014-11-19
TW201345525A (zh)	2013-11-16
EA028984B1 (ru)	2018-01-31
US9795596B2 (en)	2017-10-24
IN2014DN08970A (es)	2015-05-22
NZ628596A (en)	2015-10-30
PH12014502168A1 (en)	2014-12-10
ES2845560T3 (es)	2021-07-27
BR112014023530A2 (pt)	2017-07-18
SG10201608001RA (en)	2016-11-29
ZA201405938B (en)	2015-11-25
ECSP14025016A (es)	2015-09-30
CA2866127A1 (en)	2013-10-03
HK1200723A1 (en)	2015-08-14
US20150111927A1 (en)	2015-04-23

Similar Documents

Publication	Publication Date	Title
LTC2331537I2 (lt)	2022-01-10	1-((5-heteroariltiazol-2-il)aminokarbonil)pirolidin-2-karboksamido dariniai, kaip fosfatidilinozitolio 3-kinazės (pi3k) inhibitoriai, naudingi proliferacinių ligų gydyme
IL251647A0 (en)	2017-06-29	Parasiticidal oral veterinary compositions comprising systemically-acting active agents, methods and uses thereof
BR112015003397A2 (pt)	2019-09-24	composto, composição farmacêutica, uso do composto e método para tratar uma doença ou condição mediada por rorgammat em um paciente.
HRP20181684T1 (hr)	2018-12-14	Postupak primjene 4-((1r,3s)-6-klor-3-fenil-indan-1-il)-1,2,2-trimetil-piperazina i njegovih soli u liječenju shizofrenije
BR112015003332A2 (pt)	2017-09-26	composto, composição farmacêutica, uso do composto e método para tratar uma doença ou condição mediada por rorgammat em um paciente
BR112015003398A2 (pt)	2018-04-24	composto, composição farmacêutica, uso do composto e método para tratar uma doença ou condição mediada por rorgammat em um paciente
PT4000608T (pt)	2026-03-05	Composição farmacêutica, métodos para o tratamento e suas utilizações
BR112015002541A2 (pt)	2017-12-05	composto, composição farmacêutica, uso de um composto, e, método para tratamento de hcv em um paciente.
BR112015001098A2 (pt)	2017-08-08	composto, composição farmacêutica e método para o tratamento de uma condição de doença.
DK3385262T3 (da)	2022-10-10	4-(3h-indol-5-yl)-n-(pyridin-2-yl)pyrimidin-2-aminderivater som proteinkinaseinhibitorer, fremstillingsfremgangsmåde og medicinsk anvendelse deraf
IT1400982B1 (it)	2013-07-05	Collirio osmotico trans-epiteliale per la cura del cheratocono.
BR112013018679A2 (pt)	2016-10-18	agente para o tratamento da alopecia
CL2013003078A1 (es)	2014-05-30	Uso de una combinación farmacéutica que comprende el compuesto 1-({4-metil-5-[2-(2,2,2-trifluoro-1,1-dimetiletil)piridin-4-il]-tiazol-2-il}-amida) de 2-amida del ácido (s) pirrolidin-1,2-dicarboxílico y el inhibidor de mtor everolimus para tratar cáncer de mama; y uso de la composición farmacéutica
LT3003268T (lt)	2018-12-10	Stabilūs peroraliniai tirpalai, skirti kompleksiniam aktyviam farmaciniam ingredientui (api)
CL2014000645A1 (es)	2014-10-03	Composicion farmaceutica que comprende a) un ciclopolisacarido tal como una ciclodextrina y b) un compuesto derivado de acido hidroxamico y sus sales, util para tratar una enfermedad neoplasica o una enfermedad inmunitaria.
IL259824B (en)	2020-04-30	History of 2-[3-(azolyl)phenyl]-3,1-thiazole-5-carboxylic acid for use as drugs
ME03392B (me)	2020-01-20	Prolek derivati (e)-n-meтil-n-( (з-метi lbenzofuran-2-il)meтil)-3-(7 -okso-5 ,6, 7,8-тетrанidr0-1,8-nafтiridin-3-il)akrilamida
BR112015014885A2 (pt)	2017-07-11	combinação de agentes ativos, composição cosmética e/ou dermatológica e processo para a preparação de uma composição de agentes ativos.
ZA201401773B (en)	2015-12-23	N-[5-(aminosulfonyl)-4-methly-1,3-thiazol-2-yl]-n-methyl-2-[4-(2-[pyridinyl)phenyl]acetamide mesylate monohydrate
PT3069720T (pt)	2019-12-02	Composição farmacológica que contém derivados de glutarimida, e a aplicação da mesma no tratamento de doenças eosinofílicas
EP3004085A4 (en)	2016-12-14	IMIDAZOLE DERIVATIVES AND METHOD FOR USE THEREOF TO IMPROVE THE PHARMACOKINETICS OF A MEDICAMENT
EP2729008A4 (en)	2014-10-29	SYSTEMS, METHODS AND FORMULATIONS FOR THE TREATMENT OF CANCER
BR112017004694A2 (pt)	2017-12-05	composições farmacêuticas compreendendo alpelisibe
BR112014031512A2 (pt)	2017-08-01	composição cosmética e método para o tratamento cosmético.
LT2939665T (lt)	2019-07-25	Farmacinė kompozicija, skirta živ infekcijų gydymui